EZH2 Protein Increases Hormone Resistant Prostate Cancer and Opens up New Way for Treating Prostate Cancer
Scientists have identified that the EZH2 protein found in prostate cancer that has become advanced could be responsible for preventing the efficacy of hormone-blocking drugs.
This discovery is very important as it can lead to discovery of a new way of treating cancer of the prostate.
In an online post made in Daily RX January 16, 2013 details of this discovery has been highlighted. Excerpts from the online article reveal the following details:
EZH2 is a protein that increases in prostate cancer that no longer responds to hormone-based therapy.
Scientists have recently identified a molecular mechanism in this protein that enables advanced tumors to spread. This discovery opens the pathway to potential new treatment.
Myles Brown, MD, professor of medicine at Harvard Medical School and director of the Center for Functional Cancer Epigenetics at the Dana-Farber Cancer Institute in Boston, led the research.
The lab study revealed that the EZH2 protein is activating cell-growth genes in advanced prostate cancer, even in the absence of male hormones called androgens.
EZH2 protein levels dramatically increase in late-stage castration-resistant prostate cancer (CRPC). Spurred by hormone production, this type of cancer can often be suppressed for a time through “surgical castration” or by administering hormone-blocking drugs.
Some hormone-based therapy drugs are leuprolide (Lupron, Viadur, Eligard), goserelin (Zoladex), triptorelin (Trelstar) and histrelin (Vantas).
After a few years, these cancers often change and no longer respond to hormone-based therapy. Investigators found that EZH2 may be the culprit for this cancer growth. The protein appears to turn on a function that spurs the spread of these tumors.
Based on these results, the authors of the study suggest that drugs designed to inhibit this function of EZH2 might be effective for treating CRPC tumors.
EZH2 is part of a protein complex that normally shuts off the expression of genes. Dr. Brown and his colleagues found that the protein is working in a different mode in prostate cancer, activating cell growth.
Drugs aimed at stopping EZH2 activity are being tested in other cancers, where they are designed to block the protein’s gene-suppressing role.
Dr. Brown added that the EZH2 protein itself is turned on by a molecular signaling pathway known as PI3K, or PI3 kinase. Several PI3K inhibiting drugs are in clinical trials at present. Brown said that a combination of drugs to inhibit both that pathway and the EZH2 protein might be another way to attack these resistant prostate cancers.
Conclusively, it’s good to know that scientists have identified the role of the EZH2 protein in spreading prostate cancer.
Obviously, this discovery can lead to the discovery of new therapies or treatments for prostate cancer; this is because more research will now focus on blocking this protein.
Details of these findings have been published in the December 2012 edition of the “Science”.
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:
(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)
- Scientists Discover a Molecular Switch Which Could Cause the Spread of Castration – Resistant Prostate Cancer
- About New Report on Hormone Refractory (Castration Resistant, Androgen-independent) Prostate Cancer – Pipeline Review H2, 2012″
- Cabozantinib (XL184) effective in Treating Castration-Resistant Prostate Cancer (CRPC) – Study
- Scientists Identify a Protein that May Cause Aggressive Prostate Cancer
- Cabozantinib Shows More Efficacy in Treating Metastatic Castration-Resistant Prostate Cancer (CRPC)
- Hormone Treatment Prostate Cancer Information
- MicroRNA 125b, a Molecule and new Target for Castration Resistant Prostate Cancer Identified
- Protein SPDEF in Prostate Cancer Cells Don’t Survive Possible Metastasis Sites
- Protein Compositions in Gene Alterations Could Lead To New Discoveries in Drugs And Diagnostic Methods For Prostate Cancer
- Researchers Discover New Functions of PARP-1 Inhibitor in Treating Advanced Prostate Cancer
- Hormone Treatment and Radiotherapy in Prostate Cancer
- Management of Castration-Resistant Prostate Cancer
- How Hormone Refractory Prostate Cancer (HRPC) is Treated
- Night Shift Increases The Risk of Prostate Cancer – Study
- Treating Prostate Cancer Using Green Tea